Apr 23 |
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
|
Apr 11 |
Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock
|
Mar 20 |
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
|
Mar 4 |
Aclaris (ACRS) Upgraded to Buy: Here's Why
|
Mar 4 |
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
|
Mar 1 |
Aclaris Therapeutics Full Year 2023 Earnings: Beats Expectations
|
Feb 29 |
Analysts Have Just Cut Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Revenue Estimates By 51%
|
Feb 27 |
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
|
Feb 27 |
Aclaris Therapeutics GAAP EPS of -$0.02 beats by $0.31, revenue of $17.6M beats by $12.55M
|
Feb 27 |
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
|